These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Robertson L, Yeoh SE, Stansby G, Agarwal R. Cochrane Database Syst Rev; 2017 Aug 23; 8(8):CD010837. PubMed ID: 28832905 [Abstract] [Full Text] [Related]
7. Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty. He ML, Xiao ZM, Lei M, Li TS, Wu H, Liao J. Cochrane Database Syst Rev; 2012 Jan 18; 1():CD008207. PubMed ID: 22258981 [Abstract] [Full Text] [Related]
8. Home versus in-patient treatment for deep vein thrombosis. Othieno R, Okpo E, Forster R. Cochrane Database Syst Rev; 2018 Jan 09; 1(1):CD003076. PubMed ID: 29315455 [Abstract] [Full Text] [Related]
9. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters. Schoot RA, Kremer LC, van de Wetering MD, van Ommen CH. Cochrane Database Syst Rev; 2013 Sep 11; (9):CD009160. PubMed ID: 24026801 [Abstract] [Full Text] [Related]
10. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Robertson L, Strachan J. Cochrane Database Syst Rev; 2017 Feb 14; 2(2):CD006771. PubMed ID: 28195640 [Abstract] [Full Text] [Related]
11. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Lancet; 2012 Aug 11; 380(9841):565-71. PubMed ID: 22883507 [Abstract] [Full Text] [Related]
13. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE. Robertson L, Yeoh SE, Stansby G, Agarwal R. Cochrane Database Syst Rev; 2015 Mar 06; (3):CD010837. PubMed ID: 25749503 [Abstract] [Full Text] [Related]
14. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Circulation; 2010 Mar 09; 121(9):1069-77. PubMed ID: 20176986 [Abstract] [Full Text] [Related]
15. Statin use and the prevention of venous thromboembolism: a meta-analysis. Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI. Int J Clin Pract; 2010 Sep 09; 64(10):1375-83. PubMed ID: 20716146 [Abstract] [Full Text] [Related]
16. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Perez A, Bartholomew JR. Cleve Clin J Med; 2010 Mar 09; 77(3):191-4. PubMed ID: 20200169 [Abstract] [Full Text] [Related]